Are SNPs Affecting Your PCR Efficiency?
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, provides an overview in the latest issue of its quarterly newsletter, DECODED, of the importance of checking for single nucleotide polymorphisms (SNPs) when designing PCR assays. If PCR is performed using primers that overlap a SNP, the SNP can impact the progress of the PCR, and thus the accuracy of resulting data. The presence of SNPs can influence both primer and probe Tm, the efficiency of the polymerase extension, and target specificity. It is therefore essential that researchers assess whether a candidate sequence contains SNPs, and avoid designing primers and probe over SNP containing sequences. Providing researchers with peace of mind, the IDT PrimeTime qPCR Assays are developed using a proprietary design engine that checks each sequence against up-to-date SNP and intron/exon junction locations.
To find out more about how to ensure that your PCR assays are as efficient as possible, read the article, “When Designing PCR Assays, Always Check for SNPs”, which is available in the latest issue of DECODED.
For more information please visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.